Early HLA-B*57-restricted CD8+T lymphocyte responses predict HIV-1 disease progression

Journal of Virology

Volumn 86, Issue 19, 2012, Pages 10505-10516

  Brennan, Catherine A ^a   Javier Ibarrondo, F ^a   Sugar, Catherine A ^b   Hausner, Mary Ann ^a   Shih, Roger ^a   Ng, Hwee L ^a   Detels, Roger ^b   Margolick, Joseph B ^c   Rinaldo, Charles R ^d   Phair, John ^e   Jacobson, Lisa P ^c   Yang, Otto O ^a   Jamieson, Beth D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; HLA B57 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS 1 PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; NEF PROTEIN; POL PROTEIN; REV PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS ENVELOPE PROTEIN; VPR PROTEIN; VPU PROTEIN;

ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EPITOPE MAPPING; GENETIC CONSERVATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN TARGETING; RETROSPECTIVE STUDY; SEROCONVERSION; T LYMPHOCYTE ACTIVATION; VIREMIA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DISEASE PROGRESSION; EPITOPES; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE EXPRESSION REGULATION, VIRAL; HIV-1; HLA-B ANTIGENS; HUMANS; MALE; MODELS, STATISTICAL; PEPTIDES; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84868675469     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00102-12     Document Type: Article

References (87)

1. Addo MM, et al. 2003. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 77:2081-2092.
2. + T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J. Virol. 79:13239-13249.
3. Altfeld M, et al. 2003. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 17:2581-2591.
4. Altfeld M, et al. 2006. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(+) T cell response against HIV-1. PLoS Med. 3:e403. doi:10.1371/journal.pmed.0030403.
5. Bailey JR, Williams TM, Siliciano RF, Blankson JN. 2006. Maintenance of viral suppression in HIV-1-infected HLA-B*57Universal-GreekwithMathPi.-1.H11001 elite suppressors despite CTL escape mutations. J. Exp. Med. 203:1357-1369.
6. Balamurugan A, Ng HL, Yang OO. 2010. Rapid T cell receptor delineation reveals clonal expansion limitation of the magnitude of the HIV-1specific CD8+ T cell response. J. Immunol. 185:5935-5942.
7. Bansal A, et al. 2005. CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides. AIDS 19:241-250.
8. Betts MR, et al. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107:4781-4789.
9. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103-6110.
10. Boutwell CL, Rowley CF, Essex M. 2009. Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. J. Virol. 83:2460-2468.
11. Brockman MA, et al. 2010. Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J. Virol. 84:11937-11949.
12. Brumme ZL, et al. 2008. Marked epitopeand allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection. J. Virol. 82:9216-9227.
13. + T cell immunity and viral escape following acute HIV-1 infection. J. Immunol. 171:3837-3846.
14. Cao K, et al. 2001. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum. Immunol. 62:1009-1030.
15. Chen H, et al. 2011. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J. Clin. Invest. 121:1549-1560.
16. Chen H, et al. 2009. Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J. Virol. 83:3138-3149.
17. Crawford H, et al. 2009. Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients. J. Exp. Med. 206:909-921.
18. Deeks SG, Walker BD. 2007. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27:406-416.
19. Detels R, et al. 2012. The Multicenter AIDS Cohort Study, 1983 to... Public Health 126:196-198.
20. Detels R, et al. 1992. Recent scientific contributions to understanding HIV/AIDS from the Multicenter AIDS Cohort Study. J. Epidemiol. 2:S11-S19.
21. + T-cell responses better define HIV disease progression than HLA genotype. J. Virol. 84:4461-4468.
22. Dudley J, et al. 1995. The Multicenter AIDS Cohort Study: retention after 9 1/2 years. Am. J. Epidemiol. 142:323-330.
23. + T-cell responses to the Gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J. Virol. 76:2298-2305.
24. + T cells evade Treg cell suppression. Nat. Med. 17:989-995.
25. Emu B, et al. 2008. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J. Virol. 82:5398-5407.
26. Fellay J, et al. 2007. A whole-genome association study of major determinants for host control of HIV-1. Science 317:944-947.
27. Frahm N, et al. 2006. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat. Immunol. 7:173-178.
28. Frahm N, et al. 2007. Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur. J. Immunol. 37:2419-2433.
29. Gao X, et al. 2005. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat. Med. 11:1290-1292.
30. Goepfert PA, et al. 2008. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J. Exp. Med. 205:1009-1017.
31. Goonetilleke N, et al. 2009. The first T cell response to transmitted/ founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206:1253-1272.
32. Goulder PJ, et al. 2001. Substantial differences in specificity of HIVspecific cytotoxic T cells in acute and chronic HIV infection. J. Exp. Med. 193:181-194.
33. Goulder PJ, et al. 1996. Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res. Hum. Retroviruses 12:1691-1698.
34. Horton H, et al. 2006. Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection. J. Immunol. 177:7406-7415.
35. + T-lymphocyte responses in blood and mucosa during chronic infection. J. Virol. 79:4289-4297.
36. Jamieson BD, et al. 2003. Epitope escape mutation and decay of human immunodeficiency virus type 1-specific CTL responses. J. Immunol. 171: 5372-5379.
37. Jones N, et al. 2003. Evaluation of antigen-specific responses using in vitro enriched T cells. J. Immunol. Methods 274:139-147.
38. Kaslow RA, et al. 1996. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2:405-411.
39. Kaslow RA, et al. 1987. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am. J. Epidemiol. 126:310-318.
40. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13:46-53.
41. Kim AY, et al. 2011. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology 140:686-696.e1. doi:10.1053/j.gastro.2010.09.042.
42. Korber BT, et al. 1994. Genetic differences between bloodand brainderived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J. Virol. 68:7467-7481.
43. Košmrlj A, et al. 2010. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 465:350-354.
44. Koup RA, et al. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
45. Lambotte O, et al. 2005. HIV controllers: a homogeneous group of HIV1-infected patients with spontaneous control of viral replication. Clin. Infect. Dis. 41:1053-1056.
46. Lassen KG, et al. 2009. Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog. 5:e1000377. doi:10.1371/journal.ppat.1000377.
47. + T cells after early HIV-1 infection. J. Virol. 81:4199-4214.
48. Liu Y, et al. 2009. Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses. J. Infect. Dis. 200:1825-1833.
49. Lobritz MA, Lassen KG, Arts EJ. 2011. HIV-1 replicative fitness in elite controllers. Curr. Opin. HIV AIDS 6:214-220.
50. Magurran AE. 2004. Measuring biological diversity. Blackwell, Oxford, United Kingdom.
51. Martinez-Picado J, et al. 2006. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J. Virol. 80:3617-3623.
52. + T cells: correlation with viral load. J. Virol. 78:3233-3243.
53. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. 2010. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10:11-23.
54. Migueles SA, Connors M. 2010. Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV. JAMA 304:194-201.
55. + T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29:1009-1021.
56. Migueles SA, et al. 2000. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. U. S. A. 97:2709-2714.
57. + T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J. Virol. 83:11876-11889.
58. Navis M, et al. 2007. Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J. Immunol. 179: 3133-3143.
59. Novitsky V, et al. 2003. Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection. J. Virol. 77:882-890.
60. O'Connell KA, Bailey JR, Blankson JN. 2009. Elucidating the elite: mechanisms of control in HIV-1 infection. Trends Pharmacol. Sci. 30: 631-637.
61. Pelak K, et al. 2010. Host determinants of HIV-1 control in African Americans. J. Infect. Dis. 201:1141-1149.
62. Pereyra F, et al. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197:563-571.
63. Pereyra F, et al. 2010. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330:1551-1557.
64. Peters B, et al. 2005. The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol. 3:e91. doi:10.1371/journal. pbio.0030091.
65. Rao X, Hoof I, Costa AI, van Baarle D, Keşmir C. 2011. HLA class I allele promiscuity revisited. Immunogenetics 63:691-701.
66. + T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J. Virol. 82:3391-3404.
67. + T cells from HIV controllers. Blood 118:955-964.
68. Sáez-Cirión A, et al. 2007. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. 104:6776-6781.
69. Sáez-Cirión A, Pancino G, Sinet M, Venet A, Lambotte O. 2007. HIV controllers: how do they tame the virus? Trends Immunol. 28:532-540.
70. Sáez-Cirión A, et al. 2009. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J. Immunol. 182:7828-7837.
71. Scheid JF, et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636-640.
72. + lymphocytes. Science 283:857-860.
73. Schneidewind A, et al. 2009. Maternal transmission of human immunodeficiency virus escape mutations subverts HLA-B57 immunodominance but facilitates viral control in the haploidentical infant. J. Virol. 83:8616-8627.
74. Shacklett BL, et al. 2003. Optimization of methods to assess human mucosal T-cell responses to HIV infection. J. Immunol. Methods 279: 17-31.
75. Simpson EH. 1949. Measurement of diversity. Nature 163:688.
76. + T cells. PLoS Med. 5:e100. doi:10.1371/journal.pmed.0050100.
77. + T cells. J. Virol. 83:7641-7648.
78. + T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles. J. Virol. 81:7725-7731.
79. Streeck H, Nixon DF. 2010. T cell immunity in acute HIV-1 infection. J. Infect. Dis. 202(Suppl. 2):S302-S308.
80. + T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently. J. Immunol. 176:6130-6146.
81. Turnbull EL, et al. 2009. Kinetics of expansion of epitope-specific T cell responses during primary HIV-1 infection. J. Immunol. 182:7131-7145.
82. + T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1. J. Virol. 83:1845-1855.
83. Wong JT, Colvin RB. 1987. Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens. J. Immunol. 139:1369-1374.
84. + T cell subsets with bispecific monoclonal antibodies: evidence for inter-T cell-mediated cytolysis. Clin. Immunol. Immunopathol. 58:236-250.
85. Yang OO. 2009. Candidate vaccine sequences to represent intraand inter-clade HIV-1 variation. PLoS One 4:e7388. doi:10.1371/journal. pone.0007388.
86. Yang OO, et al. 2005. Genetic and stochastic influences on the interaction of human immunodeficiency virus type 1 and cytotoxic T lymphocytes in identical twins. J. Virol. 79:15368-15375.
87. Yang OO, Daar ES, Ng HL, Shih R, Jamieson BD. 2011. Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia. AIDS Res. Hum. Retroviruses 27:391-398.